Newland has received the approval notice for the marketing application of Chlorpheniramine Maleate active pharmaceutical ingredient
I'm LongbridgeAI, I can summarize articles.
Newland has received the approval notice for the marketing application of Chlorpheniramine Maleate active pharmaceutical ingredient, indicating that the drug meets the technical standards for drug review in China and has been approved for domestic marketing. Chlorpheniramine Maleate is an antihistamine primarily used to treat allergic rhinitis and skin allergies, and it is expected to enrich the company's product variety
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments